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Abstract: G protein coupled receptors (GPCRs) are the most historically successful therapeutic targets. Despite this suc-
cess there are many important aspects of GPCR pharmacology and function that have yet to be exploited to their full 
therapeutic potential. One in particular that has been gaining attention in recent times is that of GPCR ligands that bind to 
allosteric sites on the receptor distinct from the orthosteric site of the endogenous ligand. As therapeutics, allosteric 
ligands possess many theoretical advantages over their orthosteric counterparts, including more complex modes of action, 
improved safety, more physiologically appropriate responses, better target selectivity, and reduced likelihood of desensiti-
sation and tachyphylaxis. Despite these advantages, the development of allosteric ligands is often difficult from a medici-
nal chemistry standpoint due to the more complex challenge of identifying allosteric leads and their often flat or confusing 
SAR. The present review will consider the advantages and challenges associated with allosteric GPCR ligands, and exam-
ine how the particular properties of these ligands may be exploited to uncover the therapeutic potential for free fatty acid 
sensitive GPCRs. 
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INTRODUCTION 
G protein-coupled receptors (GPCRs) comprise the larg-
est family of membrane bound signal transduction proteins. 
These receptors are defined by their 7 transmembrane struc-
ture and ability to transmit intracellular signaling responses, 
primarily through the activation of guanine nucleotide bind-
ing G proteins, to a wide range of extracellular stimuli rang-
ing from photons of light, to peptides, lipids, neurotransmit-
ters and hormones. It is this ability to generate intracellular 
responses to extracellular stimuli that has made GPCRs the 
most historically successful drug targets, with recent esti-
mates suggesting at least 30% of currently available thera-
peutics act via this family of receptor. Despite their success 
as drug targets, only a small fraction of known GPCRs are 
currently targeted, suggesting that GPCRs remain a largely 
untapped therapeutic resource. 
In recent times it has become clear that a number of 
metabolic intermediates, previously believed to exert their 
biological effects via intracellular targets, are also capable of 
activating GPCRs. Of particular interest is a group of GPCRs 
found to respond to free fatty acids. These include a family 
of three closely related receptors originally named GPR40, 
GPR43 and GPR41 [1], which have now been grouped into 
the free fatty acid (FFA) family and renamed FFA1, FFA2 
and FFA3 respectively [2], as well as at least two additional 
receptors officially still classified as orphans, GPR120 and 
GPR84. Although these receptors all respond to free fatty 
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acid ligands, the specific fatty acids able to activate each 
receptor varies greatly depending on both chain length and 
extent of saturation. For example, among the FFA family 
members, FFA1 is activated by medium and long chain (be-
tween 6 and 23 carbon) saturated and unsaturated fatty acids 
[3,4], while both FFA2 and FFA3 respond only to short 
chain fatty acids (SCFAs) (up to 6 carbon) [5-7]. GPR120 
responds primarily to long chain (16-22 carbon) unsaturated 
fatty acids [8], with a preference sometimes reported for n-3 
fatty acids [9], while GPR84 responds to medium chain 
length (8-12 carbon) saturated fatty acids [10]. 
Each of these receptors has generated some interest in 
drug development programmes, most commonly for the 
treatment of either metabolic or inflammatory conditions 
[11-17]. To date, FFA1 has received the most attention, spe-
cifically for the treatment of type 2 diabetes, due to its ex-
pression in pancreatic ? cells and ability to enhance glucose-
stimulated insulin secretion (GSIS) [4]. Indeed, at least two 
FFA1 agonists have progressed into clinical trials for the 
treatment of type 2 diabetes (Fig. (1)); TAK-875 (1) [18] and 
AMG 837 (2) [19], with phase II results for 1 showing great 
promise [20].  
Although FFA1 has received the most attention, substan-
tial interest in the other free fatty acid sensitive GPCRs is 
also evident. Despite such interest, several experimental 
challenges associated with these receptors have slowed their 
progression through the drug development process [14]. 
These issues have included difficulties in identifying potent 
and selective ligands, and species orthologue differences in 
ligand pharmacology and, potentially, expression pattern. 
Moreover, concerns over receptor desensitisation in 
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Fig. (1). FFA1 agonists in clinical trials. 
 
situations in which agonism would appear to be the preferred 
mode of action have been discussed, whilst there are other 
situations where basic and pre-clinical studies have failed to 
define clearly whether agonism or antagonism might be the 
most effective strategy. One drug development approach that 
may be considered to address and potentially overcome 
many of these issues is the development of ligands that in-
stead of binding to the orthosteric site of the endogenous 
ligand(s), interact with a distinct allosteric site. In the present 
review we will consider the advantages and disadvantages to 
such an approach to drug development at GPCRs, and exam-
ine how this specifically might apply to the receptors for free 
fatty acids. 
ALLOSTERIC MODULATION OF GPCRs 
The concept that a molecule binding to a distinct site on a 
protein may be capable of altering the conformation of that 
protein so as to modulate function was first described as ‘al-
losterism’ in the 1960’s [21, 22]. This concept has proven 
very useful in drug development, particularly for therapeu-
tics targeting ion channels. In contrast, identification and 
understanding of allosteric modulation of GPCRs has been 
slower to develop. At least historically, in large part, this has 
been due to prevalent use of competitive radioligand binding 
assays to screen for and characterise novel GPCR ligands, an 
approach not well suited to identifying allosteric compounds 
[23, 24]. However, the interest in allosteric modulators of 
GPCRs has received increased attention in recent years [23-
28], and indeed at least two GPCR allosteric modulators are 
now approved for clinical use [24]. 
Although the classic view of allosterism holds that a 
ligand binding at one site will result in a change in confor-
mation that alters the function or affinity of a ligand at the 
second site, this definition is generally modified slightly 
when used in the context of GPCRs. In this case, a ligand is 
termed to be ‘allosteric’ so long as it binds to a site on the 
receptor distinct from that of the endogenous ligand, the ‘or-
thosteric’ binding site. Under this definition allosteric 
ligands may exert effects through one of two mechanisms 
(Fig. (2)): 1) The classic view of allosteric modulation where 
binding of the allosteric ligand modulates the properties of 
the orthosteric site; or 2) by directly altering receptor func-
tion independent of the orthosteric site. An allosteric ligand 
may modulate the orthosteric binding site of a GPCR in sev-
eral ways, specifically through alteration of either affinity or 
efficacy. In cases where an allosteric ligand enhances affin-
ity/efficacy it is described as a positive allosteric modulator 
(PAM), while in cases where the allosteric ligand decreases 
affinity/efficacy it is referred to as a negative allosteric 
modulator (NAM). Allosteric ligands that directly activate 
the receptor (independent of ligand binding at the orthosteric 
site) are described as allosteric agonists. Further complicat-
ing the issue, a single allosteric ligand may possess any 
combination of these properties, with one common example 
being the so-called ‘ago-allosteric’ modulators, which are 
both allosteric agonists and PAMs. However, this does not 
represent the only possible scenario and indeed allosteric 
ligands have been described that at the same time act as both 
a PAM of affinity and NAM of efficacy [29]. Although this 
complexity may make defining the properties of allosteric 
ligands challenging, it is also potentially one of the key ad-
vantages that make allosteric ligands attractive in drug dis-
covery. 
PHARMACOLOGICAL ADVANTAGES OF ALLOS-
TERIC GPCR LIGANDS 
There are several attributes of allosteric ligands that 
make them particularly appealing as therapeutics. The first 
is, as noted above, the varying detail of their potential ef-
fects. At least conceptually, an allosteric ligand with a com-
plex mode of action has the potential to produce a more 
finely tailored biological response than a typical orthosteric 
agonist or antagonist and, therefore, could be used to de-
velop therapeutics with both improved efficacy and reduced 
toxicity. Identifying ligands that produce unique functional 
responses has generated substantial interest lately, although 
more commonly as it relates to the concept of GPCR func-
tional selectivity or ligand bias [30, 31]. It has become ap-
parent that GPCRs may adopt several different active con-
formations each capable of producing its own unique set of 
signaling outcomes. Ligands capable of selectively stabilis-
ing one specific active state over the others will therefore 
direct receptor signaling through the pathway(s) associated 
with this active state, thus leading to a unique functional 
response [32, 33]. Conceptually, this could be the basis for a 
ligand that activates pathways associated with therapeutic 
benefit, but not pathways associated with adverse side ef-
fects. Although this concept applies also to orthosteric 
ligands, and indeed many functionally selective orthosteric 
ligands have been described [31, 34, 35]; the complex be-
havior of allosteric ligands, along with the fact that they may 
bind to many different sites, suggests that functional selec-
tivity will likely be much more common among allosteric 
ligands. 
The second major advantage of developing GPCR allos-
teric ligands as therapeutics is that many only produce an 
effect in a physiological context when an endogenous orthos-
teric agonist is also present (with allosteric agonists being 
the obvious exception). Particularly in cases where agonism 
is preferred this property provides numerous theoretical 
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Fig. (2). Complex pharmacological properties of allosteric ligands. A) The effect of a PAM of affinity (dark grey) or efficacy (light grey) 
on the orthosteric ligand response at a representative GPCR. The PAM binding to a distinct site from the orthosteric agonist (black) alters the 
receptor conformation so as to increase affinity or efficacy. The resulting concentration-response for the orthosteric agonist in the presence of 
a single concentration of each PAM is shown. A shift to higher potency for the PAM of affinity and an increased maximal response for the 
PAM of efficacy are apparent. B) The effect of a NAM of affinity (dark grey) or efficacy (light grey) on the orthosteric ligand response at a 
representative GPCR. The NAM binds to a distinct site to decrease the affinity or efficacy of the orthosteric agonist. The resulting concentra-
tion-response to the orthosteric agonist in the presence of single concentration of each NAM shows a shift to lower potency for the NAM of 
affinity, and a decreased maximal response for the NAM of efficacy. C) The effect of an allosteric modulator (either a PAM or NAM; dark 
grey) compared with a full allosteric agonist (light grey) on the GPCR in the absence of orthosteric ligand. While no response is observed 
with the modulator, the allosteric agonist produces a full signaling response even in the absence of an orthosteric agonist. In this example the 
potency of the allosteric agonist is approximately equivalent to the potency of the orthosteric agonist. D) Examples of more complex modes 
of action for allosteric ligands of GPCRs. The ago-allosteric modulator (dark grey) binds to a distinct site and activates the receptor, but also 
enhances the affinity for the orthosteric agonist. The resulting concentration-response to the orthosteric ligand shows an elevated basal signal 
due to the allosteric agonism properties of the ligand, combined with a shift to higher orthosteric ligand potency resulting from the PAM 
property. An example of a ligand that is a PAM of affinity, but a NAM of efficacy is also shown (light grey). In this case, the concentration 
response to the orthosteric ligand is shifted to lower concentrations due to the PAM effect, while the maximal response is decreased as a re-
sult of the NAM properties of the ligand. 
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benefits including improved safety, decreased risk of desen-
sitisation, and more physiologically appropriate temporal 
and special patterns of receptor activation [25, 26, 28]. 
One of the key distinguishing properties of a PAM or 
NAM compound is that because it binds to a distinct site, 
and therefore is not directly competitive with the endogenous 
ligand, its effect are expected to be saturable. This provides a 
built-in maximum response to the ligand, thus reducing the 
likelihood of overdose. This has, for example, been critical 
to developing safe potentiators of the GABAA receptors [36] 
and although this example is a ligand-gated ion channel, the 
same principles should apply to developing allosteric modu-
lators of GPCRs where overdose may be a concern. A sec-
ond advantage of the fact that allosteric modulators only 
produce an effect in the presence of an orthosteric ligand is 
that PAMs have a decreased likelihood of inducing receptor 
desensitisation. Developing agonist ligands for GPCRs is 
often challenging since most are rapidly phosphorylated and 
trafficked away from the cell surface after activation by high 
efficacy agonists. This is not a general concern for the action 
of endogenous agonist ligands that are normally released on 
demand and are present in the vicinity of the GPCR only for 
a short time. In contrast, a pharmaceutical agent is typically 
maintained at a concentration sufficiently high to occupy a 
substantial proportion of the GPCR, and as a result, desensi-
tisation and internalisation could easily lead to drug toler-
ance or tachyphylaxis. The development of PAMs is an ob-
vious solution to this problem since they should not maintain 
this constant high level of receptor activation. A closely re-
lated advantage of PAMs is that, again because they require 
the presence of the endogenous ligand to produce response, 
the temporal and special aspects of their effects should be 
more physiologically appropriate. Perhaps this is of most 
value within the central nervous system, where being able to 
potentiate a neurotransmitter response only at active syn-
apses has obvious advantages over globally activating the 
neurotransmitter’s receptor [26]; however, there are many 
other systems where this property of a PAM would make it 
an appealing option over a classic orthosteric agonist as well. 
The third major advantage of allosteric ligands for 
GPCRs is that they provide an alternate means to develop 
selective ligands for closely related receptors activated by a 
common endogenous ligand. In these cases, due to the evolu-
tionary pressure to maintain response to the common en-
dogenous ligand, it is not surprising that often the orthosteric 
binding sites among the individual GPCRs of such families 
are very similar. As a result, developing selective orthosteric 
ligands within these families has often been challenging. In 
contrast, since there is no evidence that allosteric binding 
sites would be subjected to similar evolutionary pressures, 
unless they are integral to protein folding and shape, it 
should be much easier to identify allosteric ligands that will 
distinguish between closely related receptors. Such has been 
the case in developing selective allosteric agonists for indi-
vidual subtypes of both muscarinic [37] and metabotropic 
glutamate receptors [38]. Finally, since a GPCR presumably 
has only one orthosteric binding site, yet may have multiple 
allosteric sites as evidenced by detailed studies of for exam-
ple muscarinic acetylcholine [37] and FFA1 receptors [39], 
developing allosteric ligands also represents a viable strategy 
in situations where the orthosteric site is simply not amena-
ble to drug development. 
Challenges Associated with Allosteric GPCR Ligands 
While there are many theoretical advantages of allosteric 
ligands of GPCRs, there are also a number of challenges 
associated with their development. These begin with the ear-
liest stages of lead identification, a process typically carried 
out through either structure- or ligand-based screening ap-
proaches. Historically, structure-based screening has been 
challenging at GPCRs, due to the difficulty in obtaining suf-
ficiently detailed structural information at these receptors. 
Although atomic level crystal structures of bovine rhodopsin 
have been available for some time [40], it is only recently 
that detailed crystal structures of additional class A rhodop-
sin-like GPCRs have started to become available [41-48] and 
indeed it is even more recent that the first NMR structure of 
a GPCR within a phospholipid bilayer has been solved [48]. 
Although the publication of these structures has opened the 
door to increased structure-based drug development through 
homology models [50, 51], this is much more challenging 
for allosteric ligands, as a suitable allosteric site must first be 
identified. Further complicating this issue, there are now 
examples of allosteric ligands that interact with both ex-
tracellular loop 2 (ECL2) [52, 53], and the intracellular car-
boxyl terminal tail [54, 55] of GPCRs, two regions that are 
poorly conserved and therefore difficult to predict through 
homology models. Considering these factors, at present it is 
clear that structure-based design approaches are often not the 
best suited to identifying novel allosteric leads. 
As a result of these challenges to structure-based screen-
ing, the majority of allosteric ligands have instead been 
identified through cell-based ligand screening. However, the 
complexity of effects allosteric ligands may have on their 
receptors means that even screening approaches are signifi-
cantly more challenging for allosteric ligands. While radio-
ligand competition assays have long been the standard ap-
proach to identify orthosteric ligands at GPCRs, these are 
poorly suited to identifying allosteric ligands. As a result, 
most screening for allosteric ligands instead utilizes cell-
based functional assays. Complicating the issue, if the de-
sired compound is an allosteric modulator (either PAM or 
NAM) the screening must be conducted in the presence of an 
orthosteric agonist. Since it is now recognised that allosteric 
modulators do not necessary produce the same effect on all 
orthosteric agonists, a phenomena described as ‘probe de-
pendence’ [25, 56], the particular orthosteric ligand chosen 
to use in the screen is critical, though in most cases the en-
dogenous ligand itself is the obvious choice. If instead the 
goal is to identify allosteric agonists, it is important to con-
firm any identified ‘hits’ are actually allosteric in nature 
through follow-up studies. 
Once a lead has been identified, allosteric ligands also 
present significant challenges to the lead optimisation phase 
of drug development. Again, due to limitations in homology 
modeling and, frequently, in defining the location of allos-
teric binding sites, ligand-based structure-activity relation-
ship (SAR) approaches are generally preferred to structure-
based options. Unfortunately, allosteric sites on GPCRs 
commonly display confusing SAR, making lead optimisation 
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difficult [57, 58]. A classic example of an allosteric site at 
which structural alterations to the lead produced little insight 
derived from efforts to identify PAMs for the metabotropic 
mGluR5 glutamate receptor. In this study only 4.5% of 985 
analogues tested were found to be active, despite the fact that 
an iterative approach to ligand optimisation was employed 
[59]. Complicating the issue further, it is not uncommon for 
very small chemical changes in allosteric ligands to result in 
profound differences to the pharmacological properties of 
the ligand, for example switching from a PAM to a NAM. 
This has been explored in greatest detail for mGluR allos-
teric ligands and, indeed, it has been proposed that ‘molecu-
lar-switches’ present within allosteric binding sites facilitate 
these vast differences in function in response to minor 
chemical alterations [60]. 
If the issues in lead identification and optimisation can be 
overcome, there are still additional challenges presented by 
allosteric ligands. As mentioned above, allosteric binding 
sites are not believed to be under the same evolutionary pres-
sures as orthosteric sites. While this may be an advantage in 
developing selective ligands for closely related GPCRs, such 
a lack of evolutionary pressure may also present a number of 
significant issues. The first of these is that it could result in 
much greater variation in the response to an allosteric ligand 
between species orthologues of a receptor [28]. Although 
this is likely to complicate the preclinical phase of drug de-
velopment, where animal models are critical, it does not nec-
essarily preclude the clinical utility of a compound. In con-
trast, a potentially much more serious problem, that is cur-
rently almost completely unexplored, is that the reduced evo-
lutionary pressure may also lead to increased polymorphisms 
within the human population affecting allosteric ligand func-
tion [28], potentially resulting in substantial populations for 
which a developed allosteric drug may not be effective. 
Taken together, it is clear that while allosteric ligands of 
GPCRs possess many theoretical advantages from the stand-
point of pharmacology, they also present a unique, and par-
ticularly challenging, problem to the medicinal chemist. De-
spite these challenges, it is likely that the benefits will out-
weigh the drawbacks, and the number of therapeutics acting 
allosterically at GPCRs will almost certainly increase in the 
coming years. Considering this, the question remains, how 
such ligands may solve the issues currently associated with 
drug development at receptors for free fatty acids. 
ALLOSTERIC LIGANDS OF FREE FATTY ACID 
RECEPTORS AS THERAPEUTICS 
All five of the GPCRs currently recognised to respond to 
free fatty acids have received at least some interest as thera-
peutic targets. This has been directed primarily towards 
metabolic and inflammatory conditions, and perhaps not 
surprisingly given its prevalence, type 2 diabetes has re-
ceived the greatest attention. The development of therapeu-
tics targeting these receptors has, however, been slowed by a 
number of specific challenges, not least the development of 
suitably selective ligands [14]. While this, and other chal-
lenges may be addressed with allosteric ligands, there has so 
far only been a limited effort aimed at identifying and char-
acterising the therapeutic potential of allosteric ligands at the 
free fatty acid receptors.  
Allosteric Ligands for FFA1 
Of the free fatty acid sensitive GPCRs, FFA1 has re-
ceived by far the most attention. This is primarily due to the 
fact that FFA1 is expressed in pancreatic ? cells and en-
hances GSIS [4]. An important feature of this action is that 
FFA1 agonists only stimulate increased insulin secretion in 
the presence of glucose, a clear advantage over traditional 
insulin secretagogues that stimulate insulin secretion regard-
less of the prevailing concentration of glucose and, as a re-
sult, are prone to inducing hypoglycemic episodes in patients 
[61]. Interestingly, this means that an orthosteric FFA1 ago-
nist produces a functional response in ? cells that is in many 
ways analogous to an allosteric modulator in which glucose 
is analogous to the endogenous orthosteric ligand. Thus, an 
FFA1 orthosteric agonist is likely to possess many of the 
benefits typically associated with allosteric modulators, in-
cluding producing physiologically appropriate temporal re-
sponses (only in the presence of elevated glucose), a de-
creased likelihood of desensitisation, and reduced incidence 
of adverse effects (hypoglycemia). As a result, the desire to 
develop allosteric modulators of FFA1 may not be as strong 
as for other receptors and, indeed, at least within publically 
available information, drug development programmes at 
FFA1 have focused entirely on finding potent and selective 
orthosteric agonists. These efforts have identified many dif-
ferent classes of FFA1 agonist, many with relatively good 
potency (Fig. (3)) [19, 62-68], all of which have been as-
sumed to be orthosteric. However, a recent study has demon-
strated that at least two of these ligands are in fact allosteric 
[39], drawing into question the previously assumed orthos-
teric mode of action of many other FFA1 agonists. 
The work to define the orthosteric binding pocket of 
FFA1 focused on the fact that both the endogenous fatty acid 
ligands and most of the known synthetic ligands possessed a 
carboxylate head group and could be considered as synthetic 
fatty acids. As a result, early modeling and mutagenesis 
studies explored key positively charged residues that might 
coordinate this carboxylate [69, 70]. These studies identified 
two arginine residues (R5.39 and R7.35) and one asparagine 
(N6.55) that when mutated resulted in a receptor with greatly 
reduced function for the synthetic agonist GW9508 (3). 
These mutations also reduced function for the endogenous 
fatty acid linoleic acid (though to a lesser degree). It was 
hence concluded that these amino acids coordinated the 
binding of both 3 and linoleic acid [70]. Although the vast 
majority of FFA1 agonist ligands possess such a carboxylate, 
notable exceptions are the thiazolidinedione compounds in-
cluding: the PPAR? activator rosiglitazone (5) [71], and an 
FFA1 selective compound developed by Merck (6) [64]. 
Interestingly, although the thiazolidinedione compounds do 
not possess a carboxylate, they were found to lose function 
at mutants of the key arginine and asparagine residues and it 
was therefore concluded that the thiazolidinedione was act-
ing as a carboxylic acid bioisostere and that these com-
pounds were acting orthosterically [72]. 
This orthosteric nature of synthetic FFA1 agonists was 
not drawn into question until very recently when it was 
shown that 2, a carboxylate containing agonist of FFA1, did 
not bind competitively with the fatty acid docosahexaenoic 
acid (7) [39]. Even more interestingly, another class of car-
boxylate containing FFA1 agonist represented by AMG 
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Fig. (3). FFA1 ligands. 
 
1638 (8), did not bind competitively with either 2 or 7. Fur-
thermore, both 2 and 8 showed positive cooperativity with 
each other as well as with 7 and therefore appear to be ago-
allosteric modulators of FFA1 [39]. This work indicates 
there are at least two allosteric binding sites on FFA1, each 
able to bind carboxylate containing ligands. A third related 
synthetic FFA1 agonist (9) binds to a site distinct from the 
allosteric sites of 2 and 8, and appears to be an orthosteric 
ligand. In most cases, the structures of allosteric ligands for a 
receptor are unrelated to its orthosteric ligand. However, for 
FFA1 this clearly does not appear to be the case, as the struc-
tures of 2, 8 and 9 must be regarded as closely related. This 
opens the possibility that other carboxylate containing FFA1 
agonists might also act as allosteric ligands. Mutation of 
R5.39 or R7.35 to alanine eliminated the response to 2, while 
it had only a small effect on the responses to 6, 8 and 9 [39]. 
This is similar to what was observed by others with complete 
loss of function for 3, and only a small reduction reported for 
linoleic acid [69, 70], suggesting that 3 most likely binds to 
the same allosteric site as 2. Clearly much more work needs 
to be done to determine exactly which FFA1 agonists are 
binding to which sites and, as described by Lin et al. [39], 
the availability of radiolabelled ligands from different 
chemical series will likely be instrumental in defining this. 
With the recognition that at least some FFA1 agonists are 
allosteric, it raises the question as to what therapeutic impli-
cations this might have. Interestingly, it has been noted that 
several FFA1 agonists, including 2, 3 and 4, are in fact par-
tial agonists compared with the endogenous fatty acids [62, 
63, 39, 73]. Given that 2 (and possibly 3 and 4) is allosteric, 
this may suggest that allosteric agonists of FFA1 produce 
different functional outcomes than their orthosteric counter-
parts. In addition to the well-established enhancement of 
GSIS, FFA1 has also been shown to stimulate the release of 
glucagon-like peptide-1 (GLP-1) [74], another promising 
property for the treatment of type 2 diabetes. Interestingly, a 
recent study demonstrated that while full agonists of FFA1 
were capable of both enhancing GSIS and stimulating GLP-1 
secretion in vivo; the partial agonist, 2, only produced the 
GSIS effect, with no observed GLP-1 secretion [73]. Such an 
observation may suggest orthosteric full agonists are likely 
to be better therapeutics than allosteric partial agonists. 
Another factor that has complicated the development of 
FFA1 as a therapeutic target is the fact that although short-
term fatty acid treatment enhances GSIS [75], chronic fatty 
acid exposure actually results in ? cell death and reduced 
insulin secretion [76]. Early studies in FFA1
-/-
 mice sug-
gested that both effects were mediated by FFA1 [77], while 
conflicting subsequent work indicates that only the positive 
effects on GSIS are FFA1-mediated [78, 79]. These conflict-
ing results led to significant controversy and confusion over 
whether agonists or antagonists of FFA1 would actually be 
most beneficial for long-term treatment. This uncertainty 
appeared to be resolved when it was demonstrated that an 
FFA1 selective agonist, 6, produced only the positive effects 
on GSIS, and did not result in toxic effects on ? cells [64]. 
However, given the findings that some FFA1 agonists are 
allosteric [39] and that there are clear differences in func-
tional outcomes between orthosteric and allosteric FFA1 
agonists [73], it is at least conceivable that the toxic effects 
of fatty acids on ? cells could still be FFA1 mediated, but 
only occur in response to full agonists, or ligands binding to 
the orthosteric site. It is plausible, therefore, that allosteric 
agonists of FFA1 may prove to be the best therapeutic op-
tion. Indeed, given that the most advanced FFA1 agonist in 
clinical trials, 1, has significant structural similarity to the 
allosteric compound 2, including the entire 4-(3-
phenylbenzyloxy)dihydrocinnamic acid scaffold and the 
same stereochemistry at the ?-carbon, it is entirely possible 
that 1 is in fact also allosteric. Considering the recently pub-
lished promising clinical trial results with 1 [20, 80], this 
compound may, in the relatively near future, represent a 
therapeutically approved allosteric agonist of FFA1. 
Allosteric Ligands for FFA2 and FFA3 
The SCFA receptors FFA2 and FFA3 have also gener-
ated interest as therapeutic targets to treat both metabolic and 
inflammatory conditions. However, the paucity of selective 
ligands capable of distinguishing between the two has pre-
sented a significant challenge in fully defining their function 
and biology [14]. Although there are differences in the rank 
order of potency of endogenous SCFAs at FFA2 compared 
with FFA3 [5, 6], the potency and selectivity of the endoge-
nous ligands is low [81]. As FFA2 and FFA3 are often co-
expressed [6, 78], this has made interrogating the function of 
one over the other difficult in the absence of receptor knock-
down or knockout strategies. Further complicating the issue 
is the recent observation that there is significant species 
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orthologue variation in both the potency and selectivity of 
the endogenous SCFAs for these receptors [82, 83], further 
highlighting the need for selective synthetic ligands that can 
distinguish between FFA2 and FFA3. 
An early attempt to identify selective orthosteric ligands 
for these receptors screened a library of small carboxylic 
acids (SCAs) and successfully identified compounds with 
reasonable selectivity both for FFA2 (Fig. (4)), tiglic acid 
(10), and FFA3, 1-methylcyclopropanecarboxylic acid (11), 
[81]. However, although these compounds are selective, their 
potency is also very low due to the small size and low bind-
ing energy of SCAs. Not surprisingly given the relatedness 
of FFA1-3, efforts to define the orthosteric binding site of 
FFA2 and FFA3 indicated that an ionic interaction between 
the key residues conserved across all three FFA family 
members: R5.39, R7.35 and H6.55 (N6.55 in FFA1) and the 
carboxylate of the ligand is the primary basis of ligand-
receptor interaction [84]. The small size of both the SCFAs 
and SCAs has led to suggestions that the orthosteric binding 
pocket of these receptors may be too small to facilitate the 
development of more potent molecules, however, the recent 
description of carboxylate containing FFA2-selective ago-
nists that appear likely to be orthosteric (12) [85, 17], as well 
as an orthosteric FFA2 inverse agonist (13) [83, 86], indi-
cates that at least for FFA2, potent orthosteric compounds 
can be identified and potentially developed. 
Challenges in identifying selective orthosteric ligands for 
FFA2 and FFA3 have resulted in some efforts towards iden-
tifying and characterising allosteric compounds for these 
receptors. In particular, (S)-4-chloro-?-(1-methylethyl)-N-2-
thiazolylbenzeneacetamide (14) was identified in a high 
throughput screen and found to be a selective ago-allosteric 
modulator of FFA2 [87]. As is often the case with allosteric 
ligands, subsequent attempts to explore the SAR of this se-
ries were unable to improve on its modest potency despite 
modification of all parts of the structure [88, 89]. Defining 
the allosteric site where 14 binds has also presented a sub-
stantial challenge, with several modeling and mutagenesis 
studies unable to determine a precise mode of binding [88-
91]. Somewhat surprisingly, although significant species 
variation has been observed among the orthosteric SCFAs at 
FFA2, 14 appears to show little variation in potency and 
activity between human, rodent [83] and bovine (unpub-
lished observation) orthologues of FFA2. There is, however, 
also some indication that 14 may produce different signaling 
responses at FFA2 than the SCFAs, specifically 14 appears 
to be a full agonist in some pathways but only a partial ago-
nist in others [89], perhaps suggesting some degree of func-
tional selectivity. This, however, needs to be more clearly 
defined in future studies. 
At present there are far fewer reports of FFA3 selective 
ligands. Currently only a single series has been disclosed 
through a patent by Arena Pharmaceuticals, including com-
pounds reported as FFA3 agonists (15) and antagonists (16) 
[92]. Although it is unclear if these compounds are orthos-
teric or allosteric, the fact that they do not contain carboxy-
lates, or obvious carboxylate bioisosteres, suggests that they 
may be allosteric in nature. Small chemical changes between 
15 and 16 result in transposition from agonism to antago-
nism, an observation similar to the molecular switches seen 
with allosteric modulators of other GPCRs [60]. Although 
indirect this may also hint that these ligands are allosteric 
modulators of FFA3. 
Although the limited availability of selective ligands has 
made it challenging to validate FFA2 or FFA3 as therapeutic 
targets, FFA2 in particular has still attracted significant in-
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Fig. (4). FFA2 and FFA3 ligands. 
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terest for the treatment of metabolic and inflammatory condi-
tions [17, 93, 94]. FFA2 agonists are reported to inhibit 
lipolysis and regulate plasma free fatty acid levels [95], en-
hance glucose uptake in adipocytes [85] and stimulate GLP-
1 release [96]; all properties indicating that agonism of FFA2 
may be beneficial for metabolic conditions. However, FFA2 
agonists, including the allosteric compound 14, also promote 
neutrophil chemotaxis [93, 97], a property potentially detri-
mental in inflammatory conditions. Indeed, FFA2
-/-
 mice 
were protected against tissue damage in a model of colitis 
[93], suggesting FFA2 antagonists, and not agonists, might 
be useful therapeutically for inflammation. These competing 
considerations may greatly complicate the development of 
FFA2 ligands and the receptor as a therapeutic target. In-
deed, this may suggest that allosteric ligands of FFA2 with 
more complex or functionally selective modes of action may 
be a good option for future development of therapeutics tar-
geting this receptor. 
Allosteric Ligands and GPR120 
Interest in GPR120 as a therapeutic target for type 2 dia-
betes was piqued with the observation that it is expressed in 
enteroendocrine cells and may mediate fatty acid-stimulated 
GLP-1 secretion [8]. The subsequent finding that GPR120 is 
also responsible for anti-inflammatory and insulin sensitizing 
effects of n-3 fatty acids only increased the level of interest 
[9]. Recent genetic data has further strengthened the case for 
GPR120 as a therapeutic target in that GPR120
-/-
 mice are 
more prone to obesity than wild type mice and that a poorly 
functional polymorphism of GPR120 has been linked to obe-
sity in a human population [98]. Finally, a systems genetics 
approach identified GPR120 as one of the top 20 genes 
whose expression level in human islets was linked to type 2 
diabetes. Specifically, GPR120 expression was decreased in 
islets isolated from the cadavers of diabetics compared to 
healthy controls [99]. Together, these findings suggest that 
GPR120 agonists might be very promising for the treatment 
of type 2 diabetes. 
Despite the interest in GPR120, validation has been 
slowed by a lack of potent and selective ligands. Although 
having only limited sequence similarity, GPR120 responds 
to the same long chain fatty acids as FFA1. To date, only 
two academic papers have reported synthetic agonists selec-
tive for GPR120 over FFA1 (Fig. (5)). The first of these re-
ported a low potency ligand (17) with poor selectivity based 
on carboxylic acid derivatives of PPAR? agonists [100], 
while the second described a significantly more potent and 
selective ligand (18) derived from a previously described 
series of FFA1 agonists [101]. Given the lack of sequence 
similarity between GPR120 and FFA1 it is perhaps surpris-
ing that a wider range of selective and potent compounds has 
not been described. This may reflect a particular challenge 
associated with developing ligands for the orthosteric bind-
ing site of GPR120 and that developing allosteric agonists 
for GPR120 may prove a useful approach to obtaining better 
selectivity in the future. 
The orthosteric binding pocket of GPR120 has been ex-
amined in some detail, primarily through homology model-
ing [100, 101, 102]. Interestingly, none of the key positively 
charged amino acids associated with fatty acid binding to the 
FFA1-3 family members are conserved in GPR120. Instead, 
each of the models identified one alternate arginine at posi-
tion 2.64 as being responsible for a key ionic interaction with 
the carboxylate head group of the ligand [100, 101, 102]. 
The importance of R2.64 to the binding and/or function of 
both endogenous fatty acids [103] and 18 [101] has now 
been verified by mutagenesis. In addition to the endogenous 
fatty acids, 17 and 18, a number of other ligands have been 
described as agonists of GPR120 [14, 16]. These include 
several disclosed in recent patents 19 [104], 20 [105], 21 
[106]; the natural product grifolic acid (22) [107]; and sev-
eral FFA1 agonists, including 3 [62] and 4 [101], that be-
sides relatively potent activity on FFA1 also exhibit 
micromolar potency on GR120. Structural examination of 
these GPR120 agonists reveals that the majority are 
elongated lipophilic compounds containing a carboxylate, 
and therefore may be regarded as fatty acid analogues and be 
expected to act at the orthosteric site. However, given the 
recent data on the non-equivalence of the mode of binding of 
apparently similar FFA1 ligands [39], this should be 
considered tentative in the absence of further information. 
The two obvious exceptions are 19 and 21, compounds 
described in patents from Banyu Pharmaceutical [104, 106]. 
The 3-hydroxyisoxazole moiety of 21 is a carboxylic acid 
bioisostere, and the compound therefore may very well be an 
orthosteric agonist. Compound 19, however, contains no 
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Fig. (5). GPR120 ligands. 
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thosteric agonist. Compound 19, however, contains no acidic 
functional group and therefore is perhaps more likely to be 
an allosteric agonist of GPR120.  
Finally, although no allosteric modulators have been re-
ported for GPR120, there may be a strong argument for their 
development. Agonist stimulation of GPR120 has been 
shown to cause rapid receptor phosphorylation [108], strong 
interaction with ?-arrestin-2 [9, 101, 103] and internalisation 
of the receptor [8, 103]. Given that agonism clearly appears 
to be the preferred mode of action for therapeutically useful 
GPR120 ligands, these properties indicate that desensitisa-
tion could present a major challenge to the future develop-
ment of such therapeutics. Considering this, a strong case 
could be made that a PAM would be the best approach for 
targeting GPR120 in order to avoid these concerns of recep-
tor desensitisation. 
Allosteric Ligands and GPR84 
The function of GPR84 remains largely unknown, with 
very few studies published on this receptor. GPR84 appears 
to be expressed primarily in immune cells [109] and, as a 
result, most work has focused on a potential role in inflam-
mation [110]. A very interesting recent model cell study has 
indicated that GPR84 expression may be markedly up regu-
lated in adipose tissue in response to macrophage infiltration, 
suggesting that GPR84 may play a role in the link between 
adiposity and diabetes [111]. However, the lack of potent 
and selective ligands for GPR84 has made studying this in 
more detail challenging. The endogenous medium chain fatty 
acids have modest potency and selectivity and no studies 
aiming to identify novel synthetic ligands have been pub-
lished. Currently the only described synthetic ligands for 
GPR84 are indol-3-calbinol (23), and 3,3’-diindolylmethane 
(24) (Fig. (6)), two compounds that were identified as surro-
gate agonists of GPR84 even before it was recognized as a 
receptor for free fatty acids [112]. Interestingly, while the 
majority of orthosteric agonists for the other free fatty acid 
receptors contain a carboxylate moiety, neither 23 nor 24 do, 
suggesting that these compounds may in fact be allosteric 
agonists, and future work should consider this possibility. 
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CONCLUSION 
Despite presenting significant technical challenges to the 
drug development process, allosteric ligands for GPCRs pro-
vide numerous theoretical advantages over their orthosteric 
counterparts. Allosteric ligands have already been described 
for two of the free fatty acid sensitive GPCRs, with poten-
tially important therapeutic implications. It also appears 
likely that several additional ligands already described for 
these receptors are in fact also allosteric, and indeed allos-
teric agonists and modulators appear destined to play a criti-
cal role in future drug development at fatty acid-sensitive 
GPCRs. 
CONFLICT OF INTEREST 
The author(s) confirm that this article content has no con-
flict of interest. 
ACKNOWLEDGEMENTS 
These studies were supported by grants from the Danish 
Council for Strategic Research 11-116196 (to TU and GM), 
the Strategic Partnership on Food & Drink Science, Scottish 
Government Programme of Research 2011-2016/Ref UGW 
854/11 (to GM) and the Canadian Institutes of Health Re-
search (fellowship to BDH). Wellcome Trust grant number 
089600/Z/09/Z (to GM). 
REFERENCES 
[1] Sawzdargo, M.; George, S.R.; Nguyen, T.; Xu, S.; Kolakowski, 
L.F.; O'Dowd, B.F. A cluster of four novel human G protein-
coupled receptor genes occurring in close proximity to CD22 gene 
on chromosome 19q13.1. Biochem. Biophys. Res. Commun., 1997, 
239(2), 543-547. 
[2] Stoddart, L.A.; Smith, N.J.; Milligan, G. International Union of 
Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: 
pharmacology and pathophysiological functions. Pharmacol. Rev., 
2008, 60(4), 405-417.  
[3] Briscoe, C.P.; Tadayyon, M.; Andrews, J.L.; Benson, W.G.; 
Chambers, J.K.; Eilert, M.M.; Ellis, C.E.; Elshourbagy, N.A.; 
Goetz, A.S.; Minnick, D.T.; Murdock, P.R.; Sauls, H.R. Jr.; 
Shabon, U.; Spinage, L.D.; Strum, J.C.; Szekers, P.G.; Tan, K.B.; 
Way, J.M.; Ignar, D.M.; Wilson, S.; Muir, A.I. The orphan G pro-
tein-coupled receptor GPR40 is activated by medium and long 
chain fatty acids. J. Biol. Chem., 2003, 278(13), 11303-11311. 
[4] Itoh, Y.; Kawamata, Y.; Harada, M.; Kobayashi, M.; Fujii, R.; 
Fukusumi, S.; Ogi, K.; Hosoya, M.; Tanaka, Y.; Uejima, H.; Ta-
naka, H.; Maruyama, M.; Satoh, R.; Okubo, S.; Kizawa, H.; Koma-
tsu, H.; Matsumura, F.; Noguchi, Y.; Shinohara, T.; Hinuma, S.; 
Fujisawa, Y.; Fujino, M. Free fatty acids regulate insulin secretion 
from pancreatic ? cells through GPR40. Nature, 2003, 422(6928), 
173-176. 
[5] Brown, A.J.; Goldsworthy, S.M.; Barnes, A.A.; Eilert, M.M.; 
Tcheang, L.; Daniels, D.; Muir, A.I.; Wigglesworth, M.J.; King-
horn, I.; Fraser, N.J.; Pike, N.B.; Strum, J.C.; Steplewski, K.M.; 
Murdock, P.R.; Holder, J.C.; Marshall, F.H.; Szekeres, P.G.; Wil-
son, S.; Ignar, D.M.; Foord, S.M.; Wise, A.; Dowell, S.J. The Or-
phan G Protein-coupled Receptors GPR41 and GPR43 are acti-
vated by propionate and other short chain carboxylic acids. J. Biol. 
Chem. 2003, 278(13), 11312-11319. 
[6] Le Poul, E.; Loison, C.; Struyf, S.; Springael, J.Y.; Lannoy, V.; 
Decobecq, M.E.; Brezillon, S.; Dupriez, V.; Vassart, G.; Van 
Damme, J.; Parmentier, M.; Detheux, M. Functional characteriza-
tion of human receptors for Short Chain fatty acids and their role in 
polymorphonuclear cell activation. J. Biol. Chem. 2003, 278(28), 
25481-25489. 
[7] Nilsson, NE.; Kotarsky, K.; Owman, C.; Olde, B. Identification of 
a free fatty acid receptor, FFA2R, expressed on leukocytes and ac-
tivated by short-chain fatty acids. Biochem. Biophys. Res. Commun. 
2003, 303(4), 1047-1052. 
[8] Hirasawa, A.; Tsumaya, K.; Awaji, T.; Katsuma, S.; Adachi, T.; 
Tamada, M.; Sugimoto, Y.; Miyazaki, S.; Tsujimoto, G. Free fatty 
acids regulate gut incretin glucagon-like peptide-1 secretion 
through GPR120. Nat. Med., 2005, 11(1), 90-94. 
[9] Oh, D.Y.; Talukdar, S.; Bae, E.J.; Imamura, T.; Morinaga, H.; Fan, 
W.; Li, P.; Lu, W.J.; Watkins, S.M.; Olefsky, J.M. GPR120 is an 
omega-3 fatty acid receptor mediating potent anti-inflammatory 
and insulin-sensitizing effects. Cell. 2010, 142(5), 687-698. 
[10] Wang, J.; Wu, X.; Simonavicius, N.; Tian, H.; Ling, L. Medium-
chain fatty acids as ligands for orphan G protein-coupled receptor 
GPR84. J. Biol. Chem., 2006, 281(45), 34457-34464.  
Allosteric Ligands and Free Fatty Acid Receptors Current Topics in Medicinal Chemistry, 2013, Vol. 13, No. 1    23 
[11] Costanzi, S.; Neumann, S.; Gershengorn, M.C. Seven transmem-
brane spanning receptors for free fatty acids as therapeutic targets 
for diabetes mellitus: pharmacological, phylogenetic and drug dis-
covery aspects. J. Biol. Chem. 2008, 283(24), 16269-16273. 
[12] Vangaveti, V.; Shashidhar, V.; Jarrod, G.; Baune, B.T.; Kennedy, 
R.L. Free fatty acid receptors: emerging targets for treatment of 
diabetes and its complications. Ther. Adv. Endocrinol. Metab., 
2010, 1(4), 165-175 
[13] Hara, T.; Hirasawa, A.; Ichimura, A.; Kimura, I.; Tsujimoto, G. 
Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic 
targets for metabolic disorders. J. Pharm. Sci., 2011, 100(9), 3594-
3601. 
[14] Hudson, B.D.; Smith, N.J.; Milligan, G. Experimental challenges to 
targeting poorly characterized GPCRs: Uncovering the therapeutic 
potential for free fatty acid receptors. Adv. Pharmacol., 2011, 62, 
175-218. 
[15] Talukdar, S.; Olefsky, J.M.; Osborn, O. Targeting GPR120 and 
other fatty acid-sensing GPCRs ameliorates insulin resistance and 
inflammatory diseases. Trends Pharmacol. Sci., 2011, 32(9), 543-
50.  
[16] Holliday, N.D.; Watson, S.-J.; Brown, A.J.H. Drug discovery op-
portunities and challenges at G protein coupled receptors for long 
chain free fatty acids. Front. Endocrinol. 2:112. 
[17] Ulven, T. Short-chain free fatty acid receptors FFA2/GPR43 and 
FFA3/GPR41 as new potential therapeutic targets. Front. Endocri-
nol. 2012, 3, 111.  
[18] Tsujiha, Y.; Ito, R.; Suzuki, M.; Harada, A.; Negoro, N.; Yasuma, 
T.; Momose, Y.; Takeuchi, K. TAK-875, an orally available G pro-
tein-coupled receptor 40/free fatty acid receptor 1 agonist, en-
hances glucose-dependent insulin secretion and improves both 
postprandial and fasting hyperglycemia in type 2 diabetic rats. J. 
Pharmacol. Exp. Ther., 2011, 339(1), 228-37. 
[19] Lin, D.C.; Zhang, J.; Zhuang, R.; Li, F.; Nguyen, K.; Chen, M.; 
Tran, T.; Lopez, E.; Lu, J.Y.; Li, X.N.; Tang, L.; Tonn, G.R.; 
Swaminath, G.; Reagan, J.D.; Chen, J.L.; Tian, H.; Lin, Y.J.; 
Houze, J.B.; Luo, J. AMG 837: A Novel GPR40/FFA1 agonist that 
enhances insulin secretion and lowers glucose levels in rodents. 
PLoS One., 2011, 6(11), e27270. 
[20] Burant, C.F.; Viswanathan, P.; Marcinak, J.; Cao, C.; Vakilynejad, 
M.; Xie, B.; Leifke, E. TAK-875 versus placebo or glimepiride in 
type 2 diabetes mellitus: a phase 2.; randomized.; double-blind.; 
placebo-controlled trial. Lancet., 2012, 6736(11), 61879-61875. 
[21] Monod, J.; Changeux, J.P.; Jacob, F. Allosteric proteins and cellu-
lar control systems. J. Mol. Biol., 1963, 6, 306-329. 
[22] Monod, J.; Wyman, J.; Changeux, J.P. On the nature of allosteric 
transitions: a plausible model. J. Mol. Biol. 1965, 12, 88-118. 
[23] Christopoulos, A.; Kenakin, T. G protein-coupled receptor alloster-
ism and complexing. Parmacol. Rev., 2002, 54(2), 323-374. 
[24] Milligan, G.; Smith, N.J. Allosteric modulation of heterodimeric G-
protein-coupled receptors. Trends Pharmacol. Sci., 2007, 28(12), 
615-620. 
[25] May, L.T.; Leach, K.; Sexton, P.M.; Christopoulos, A. Allosteric 
modulation of G protein-coupled receptors. Annu. Rev. Pharmacol. 
Toxicol., 2007, 47, 1-51. 
[26] Conn, P.J.; Christopoulos, A.; Lindsley, C.W. Allosteric modula-
tors of GPCRs: a novel approach for the treatment of CNS disor-
ders. Nat. Rev. Drug Discov. 2009, 8(1), 41-54. 
[27] Smith, N.J; Milligan, G. Allostery at G protein-coupled receptor 
homo- and heteromers: uncharted pharmacological landscapes. 
Pharmacol. Rev., 2010, 62(4), 701-725. 
[28] Müller, C.E.; Schiedel, A.C.; Baqi, Y. Allosteric modulators of 
rhodopsin-like G protein-coupled receptors: opportunities in drug 
development. Pharmacol. Ther., 2012, 135(3), 292-315. 
[29] Price, M.R.; Baillie, G.L.; Thomas, A.; Stevenson, L.A.; Easson, 
M.; Goodwin, R.; McLean, A.; McIntosh, L.; Goodwin, G.; 
Walker, G.; Westwood, P.; Marrs, J.; Thomson, F.; Cowley, P.; 
Christopoulos, A.; Pertwee, R.G.; Ross, R.A. Allosteric modulation 
of the cannabinoid CB1 receptor. Mol. Pharmacol., 2005, 68(5), 
1484-1495.  
[30] Mailman, R.B. GPCR functional selectivity has therapeutic impact. 
Trends Pharmacol. Sci., 2007, 28(8), 390-396. 
[31] Hudson, B.D.; Hébert, T.E.; Kelly, M.E.M. Ligand- and heterodi-
mer-directed signaling of the CB(1) cannabinoid receptor. Mol. 
Pharmacol., 2010, 77(1), 1-9. 
[32] Kenakin, T. Agonist-receptor efficacy. II. Agonist trafficking of 
receptor signals. Trends Pharmacol. Sci., 1995, 16(7), 232–238 
[33] Kenakin, T. Inverse, protean, and ligand-selective agonism: matters 
of receptor conformation. FASEB J., 2001, 15(3), 598–611. 
[34] Smith, N.J.; Bennett, K.A.; Milligan, G. When simple agonism is 
not enough: emerging modalities of GPCR ligands. Mol. Cell. En-
docrinol., 2011, 331(2), 241-247.  
[35] Raehal, K.M.; Schmid, C.L.; Groer, C.E.; Bohn, L.M. Functional 
selectivity at the μ-opioid receptor: implications for understanding 
opioid analgesia and tolerance. Pharmacol. Rev. 2011, 63(4), 1001-
1019. 
[36] Sigel, E.; Buhr, A. The benzodiazepine binding site of GABAA 
recepors. Trends Pharmacol. Sci., 1997, 18, 425-429. 
[37] Gregory, K.J.; Sexton, P.M.; Christopoulos A. Allosteric modula-
tion of muscarinic acetylcholine receptors. Curr. Neuropharmacol., 
2007, 5(3), 157-167. 
[38] Sheffler, D.J.; Gregory, K.J.; Rook, J.M.; Conn, P.J. Allosteric 
modulation of metabotropic glutamate receptors. Adv. Pharmacol. 
2011, 62, 37-77. 
[39] Lin, D.C.; Guo, Q.; Luo, J.; Zhang, J.; Nguyen, K.; Chen, M.; Tran, 
T.; Dransfield, P.J.; Brown, S.P.; Houze, J.; Vimolratana, M.; Jiao, 
X.Y.; Wang, Y.; Birdsall, N.J.; Swaminath, G. Identification and 
pharmacological characterization of multiple allosteric binding 
sites on the free Fatty Acid 1 receptor. Mol. Pharmacol., 2012, 
82(5), 843-859. 
[40] Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C.A.; Motoshima, 
H.; Fox, B.A.; Le Trong, I.; Teller, D.C.; Okada, T.; Stenkamp, 
R.E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A 
G protein-coupled receptor. Science. 2000, 289(5480), 739-745.  
[41] Rasmussen, S.G.; Choi, H.J.; Rosenbaum, D.M.; Kobilka, T.S.; 
Thian, F.S.; Edwards, P.C.; Burghammer, M.; Ratnala, V.R.; San-
ishvili, R.; Fischetti, R.F.; Schertler, G.F.; Weis, W.I.; Kobilka, 
B.K. Crystal structure of the human beta2 adrenergic G-protein-
coupled receptor. Nature, 2007, 450(7168), 383-287. 
[42] Warne, T.; Serrano-Vega, M.J.; Baker, J.G.; Moukhametzianov, R.; 
Edwards, P.C.; Henderson, R.; Leslie, A.G.; Tate, C.G.; Schertler, 
G.F. Structure of a beta1-adrenergic G-protein-coupled receptor. 
Nature, 2008, 454(7203), 486-491.  
[43] Jaakola, V.P.; Griffith, M.T.; Hanson, M.A.; Cherezov, V.; Chien, 
E.Y.; Lane, J.R.; Ijzerman, A.P.; Stevens, R.C. The 2.6 angstrom 
crystal structure of a human A2A adenosine receptor bound to an 
antagonist. Science, 2008, 322(5905), 1211-1217.  
[44] Rasmussen, S.G.; DeVree, B.T.; Zou, Y.; Kruse, A.C.; Chung, 
K.Y.; Kobilka, T.S.; Thian, F.S.; Chae, P.S.; Pardon, E.; Calinski, 
D.; Mathiesen, J.M.; Shah, S.T.; Lyons, J.A.; Caffrey, M.; Gell-
man, S.H.; Steyaert, J.; Skiniotis, G.; Weis, W.I.; Sunahara, R.K.; 
Kobilka, B.K. Crystal structure of the ?2 adrenergic receptor-Gs 
protein complex. Nature, 2011, 477(7366), 549-555.  
[45] Granier, S.; Manglik, A.; Kruse, AC.; Kobilka, T.S.; Thian, F.S.; 
Weis, W.I.; Kobilka, B.K. Structure of the ?-opioid receptor bound 
to naltrindole. Nature. 2012, 485(7398), 400-404.  
[46] Hanson, M.A.; Roth, C.B.; Jo, E.; Griffith, M.T.; Scott, F.L.; Rein-
hart, G.; Desale, H.; Clemons, B.; Cahalan, S.M.; Schuerer, S.C.; 
Sanna, M.G.; Han, G.W.; Kuhn, P.; Rosen, H.; Stevens, R.C. Crys-
tal structure of a lipid G protein-coupled receptor. Science, 2012, 
335(6070), 851-855. 
[47] Manglik, A.; Kruse, A.C.; Kobilka, T.S.; Thian, F.S.; Mathiesen, 
J.M.; Sunahara, R.K.; Pardo, L.; Weis, W.I.; Kobilka, B.K.; Gra-
nier, S. Crystal structure of the ?-opioid receptor bound to a mor-
phinan antagonist. Nature., 2012, 485(7398), 321-326. 
[48] Park, S.H.; Das, B.B.; Casagrande, F.; Tian, Y.; Nothnagel, H.J.; 
Chu, M.; Kiefer, H.; Maier, K.; De Angelis, A.A.; Marassi, F.M.; 
Opella, S.J. Structure of the chemokine receptor CXCR1 in phos-
pholipid bilayers. Nature, 2012, 491(7426), 779-783. 
[49] Thompson, A.A; Liu, W.; Chun, E.; Katritch, V.; Wu, H.; Vardy, 
E.; Huang, X.P.; Trapella, C.; Guerrini, R.; Calo, G.; Roth, B.L.; 
Cherezov, V.; Stevens, R.C. Structure of the nociceptin/orphanin 
FQ receptor in complex with a peptide mimetic. Nature, 2012, 
485(7398), 395-399. 
[50] Costanzi, S. Homology modeling of class a G protein-coupled 
receptors. Methods Mol. Biol. 2012, 857, 259-279. 
[51] Levit, A.; Barak, D.; Behrens, M.; Meyerhof, W.; Niv, MY. Ho-
mology model-assisted elucidation of binding sites in GPCRs. 
Methods Mol. Biol., 2012, 914, 179-205. 
[52] Avlani, V.A.; Gregory, K.J.; Morton, C.J.; Parker, M.W.; Sexton, 
P.M.; Cristopoulos, A. Critical role for the second extracellular 
loop in the binding of both orthosteric and allosteric G protein-
coupled receptors ligands. J. Biol. Chem., 2007, 282, 25677-25686. 
24    Current Topics in Medicinal Chemistry, 2013, Vol. 13, No. 1 Hudson et al. 
[53] Peeters, M.C.; Wisse, L.E.; Dinaj, A.; Vroling, B.; Vriend, G.; 
Ijzerman, A.P. The role of the second and third extracellular loops 
of the adenosine A1 receptor in activation and allosteric modula-
tion. Biochem. Pharmacol., 2012, 84(1), 76-87.  
[54] Andrews, G.; Jones, C.; Wreggett, K.A. An intracellular allosteric 
site for a specific class of antagonists of the CC chemokine G pro-
tein-coupled receptors CCR4 and CCR5. Mol. Pharmacol., 2008, 
73, 855-867. 
[55] Dowal, L.; Sim, D.S.; Dilks, J.R.; Blair, P.; Beaudry, S.; Denker, 
B.M.; Koukos, G.; Kuliopulos, A.; Flaumenhaft, R. Identification 
of an antithrombotic allosteric modulator that acts through helix 8 
of PAR1. Proc. Nat. Acad. Sci. U.S.A., 2011, 108(7), 2951-2956. 
[56] Valant, C.; Felder, C.C.; Sexton, P.M.; Christopoulos, A. Probe 
dependence in the allosteric modulation of a G protein-coupled re-
ceptor: implications for detection and validation of allosteric ligand 
effects. Mol. Pharmacol., 2012, 81(1), 41-52. 
[57] Urwyler, S. Allosteric modulation of family C G-protein-coupled 
receptors: from molecular insights to therapeutic perspectives. 
Pharmacol. Rev., 2011, 63(1), 59-126. 
[58] Decker, M.; Holzgrabe, U. M1 muscarinic acetylcholine receptor 
allosteric modulators as potential therapeutics opportunities for 
treating Alzheimer’s disease. Med. Chem. Commun., 2012, 3(7), 
752-762.  
[59] Zhao, Z.; Wisnoski, D.D.; O'Brien, J.A.; Lemaire, W.; Williams, 
D.L, Jr.; Jacobson, M.A.; Wittman, M.; Ha, S.N.; Schaffhauser, H.; 
Sur, C.; Pettibone, D.J.; Duggan, M.E.; Conn, P.J.; Hartman, G.D.; 
Lindsley, C.W. Challenges in the development of mGluR5 positive 
allosteric modulators: the discovery of CPPHA. Bioorg. Med. 
Chem. Lett., 2007, 17(5), 1386-1391. 
[60] Wood, M.R.; Hopkins, C.R.; Brogan, J.T.; Conn, P.J.; Lindsley, 
C.W. "Molecular switches" on mGluR allosteric ligands that modu-
late modes of pharmacology. Biochemistry. 2011, 50(13), 2403-10. 
[61] Barnett, A.H.; Cradock, S.; Fisher, M.; Hall, G.; Hughes, E.; Mid-
dleton, A. Key considerations around the risks and consequences of 
hypoglycaemia in people with type 2 diabetes. Int. J. Clin. Pract. 
2010, 64(8), 1121-1129. 
[62] Briscoe, C.P.; Peat, A.J.; McKeown, S.C.; Corbett, D.F.; Goetz, 
A.S.; Littleton, T.R.; McCoy, D.C.; Kenakin, T.P.; Andrews, J.L.; 
Ammala, C.; Fornwald, J.A.; Ignar, D.M.; Jenkinson, S. Pharma-
colgical regulation of insulin secretion in MIN6 cells through the 
fatty acid receptor GPR40: identification of agonist and antagonist 
small molecules. Br. J. Pharmacol., 2006, 148(5), 619-628. 
[63] Christiansen, E.; Urban, C.; Merten, N.; Liebscher, K.; Karlsen, 
K.K.; Hamacher, A.; Spinrath, A.; Bond, A.D.; Drewke, C.; Ull-
rich, S.; Kassack, M.U.; Kostenis, E.; Ulven, T. Discovery of po-
tent and selective agonists for the free fatty acid receptor 1 
(FFA1/GPR40), a potential target for the treatment of type II diabe-
tes. J. Med. Chem., 2008, 51(22), 7061-7064. 
[64] Tan, C.P.; Feng, Y.; Zhou, Y.P.; Eiermann, G.J.; Petrov, A.; Zhou, 
C.; Lin, S.; Salituro, G.; Meinke, P.; Mosley, R.; Akiyama, T.E.; 
Einstein, M.; Kumar, S.; Berger, J.P.; Mills, S.G.; Thornberry, 
N.A.; Yang, L.; Howard, A.D. Selective small-molecule agonists of 
G protein-coupled receptor 40 promote glucose-dependent insulin 
secretion and reduce blood glucose in mice. Diabetes, 2008, 57(8), 
2211-2219. 
[65] Bharate, S.B.; Nemmani, K.V.S.; Vishwakarma, R.A. Progress in 
the discovery and development of small-molecule modulators of G-
protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging 
target for type 2 diabetes. Expert Opin. Ther. Patents., 2009, 19(2), 
237-264. 
[66] Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Suzuki,M.; Tsujihata, 
Y.; Ito, R.; Harada, A.; Takeuchi, K.; Suzuki, N.; Miyazaki, J.; 
Santou, T.; Odani, T.; Kanzaki, N.; Funami, M.; Tanaka, T.; Ko-
game, A.; Matsunaga, S.; Yasuma, T.; Momose, Y. Discovery of 
TAK-875: a potent, selective and orally bioavailable GPR40 ago-
nist. Med. Chem. Lett., 2010, 1, 290-294. 
[67] Christiansen, E.; Urban, C.; Grundmann, M.; Due-Hansen, M.E.; 
Hagesaether, E.; Schmidt, J.; Pardo, L.; Ullrich, S.; Kostenis, E.; 
Kassack, M.: Ulven, T. Identification of a potent and selective free 
fatty acid rReceptor 1 (FFA1/GPR40) agonist with favorable phys-
icochemical and in vitro ADME Properties. J. Med. Chem., 2011, 
54(19), 6691-6703. 
[68] Christiansen, E.; Due-Hansen, M.E.; Urban, C.; Grundmann, M.; 
Schröder, R.; Hudson, B.D.; Milligan, G.; Cawthorne, M.A.; Kos-
tenis, E.; Kassack, M.U.; Ulven, T. Free fatty acid receptor 1 
(FFA1/GPR40) agonists: mesylpropoxy appendage lowers lipophil-
icity and improves ADME properties. J. Med. Chem. 2012, 55(14), 
6624-6628. 
[69] Tikhonova, I.G.; Sum, C.S.; Neumann, S.; Thomas, C.J.; Raaka, 
B.M.; Costanzi, S.; Gershengorn, M.C. Bidirectional.; iterative ap-
proach to the structural delineation of the functional "chemoprint" 
in GPR40 for agonist recognition. J. Med. Chem., 2007, 50(13), 
2981-2989. 
[70] Sum, C.S.; Tikhonova, I.G.; Neumann, S.; Engel, S.; Raaka, B.M.; 
Costanzi, S.; Gershengorn, M.C. Identification of residues impor-
tant for agonist recognition and activation in GPR40. J. Biol. 
Chem., 2007, 282(40), 29248-29255.  
[71] Kotarsky, K.; Nilsson, N.E.; Flodgren, E.; Owman, C.; Olde, B. A 
human cell surface receptor activated by free fatty acids and thia-
zolidinedione drugs. Biochem. Biophys. Res. Commun., 2003, 
301(2), 406-410. 
[72] Smith, N.J.; Stoddart, L.A.; Devine, N.M.; Jenkins, L.; Milligan, G. 
The action and mode of binding of thiazolidinedione ligands at free 
fatty acid receptor 1. J. Biol. Chem., 2009, 284(26), 17527-17539. 
[73] Luo, J.; Swaminath, G.; Brown, S.P.; Zhang, J.; Guo, Q.; Chen, M.; 
Nguyen, K.; Tran, T.; Miao, L.; Dransfield, P.J.; Vimolratana, M.; 
Houze, J.B.; Wong, S.; Toteva, M.; Shan, B.; Li, F.; Zhuang, R.; 
Lin, D.C. A Potent Class of GPR40 Full Agonists Engages the En-
teroInsular Axis to Promote Glucose Control in Rodents. PLoS 
One, 2012, 7(10), e46300. 
[74] Edfalk, S.; Steneberg, P.; Edlund, H. GPR40 is expressed in en-
teroendocrine cells and mediates free fatty acid stimulation of in-
cretin secretion. Diabetes, 2008, 57(9), 2280-2287. 
[75] Greenough, W.B.; Crespin, S.R.; Steinberg, D. Hypoglycaemia and 
hyperinsulinaemia in response to raised free-fatty-acid levels. Lan-
cet, 1967, 2(7530), 1334–1336. 
[76] El-Assaad, W.; Buteau, J.; Peyot, M.L.; Nolan, C.; Roduit, R.; 
Hardy, S.; Joly, E.; Dbaibo, G.; Rosenberg, L.; Prentki, M. Satu-
rated Fatty Acids Synergize with Elevated Glucose to Cause Pan-
creatic ?-Cell Death. Endocrinology, 2003, 144(9), 4154-4163. 
[77] Steneberg, P.; Rubins, N.; Bartoov-Shifman, R.; Walker, M.D.; 
Edlund, H. The FFA receptor GPR40 links hyperinsulinemia.; he-
patic steatosis.; and impaired glucose homeostasis in mouse. Cell 
Metab., 2005, 1(4), 245-258. 
[78] Kebede, M.A.; Alquier, T.; Latour, M.G.; Poitout, V. Lipid recep-
tors and islet function: therapeutic implicaitons? Diabetes Obes. 
Metab., 2009, 11(Suppl 4), 10-20. 
[79] Lan, H.; Hoos, L.M.; Liu, L.; Tetzloff, G.; Hu, W.; Abbondanzo, 
S.J.; Vassileva, G.; Gustafson, E.L.; Hedrick, J.A.; Davis, H.R. 
Lack of FFAR1/GPR40 does not protect mice from high-fat diet-
induced metabolic disease. Diabetes, 2008, 57(11), 2999-3006. 
[80] Kaku, K.; Araki, T.; Yoshinaka, R. Randomized, double-blind, 
dose-ranging study of TAK-875, a novel GPR40 agonist, in Japa-
nese patients with inadequately controlled type 2 diabetes. Diabetes 
Care, 2013, 36(2), 245-250. 
[81] Schmidt, J.; Smith, N.J.; Christiansen, E.; Tikhonova, I.G.; Grund-
mann, M.; Hudson, B.D.; Ward, R.J.; Drewke, C.; Milligan, G.; 
Kostenis, E.; Ulven, T. Selective orthosteric free fatty acid receptor 
2 (FFA2) agonists: identification of the structural and chemical re-
quirements for selective activation of FFA2 versus FFA3. J Biol 
Chem., 2011, 286(12), 10628-10640. 
[82] Hudson, B.D.; Christiansen, E.; Tikhonova, I.G.; Grundmann, M.; 
Kostenis, E.; Adams, D.R.; Ulven, T.; Milligan, G. Chemically en-
gineering ligand selectivity at the free fatty acid receptor 2 based 
on pharmacological variation between species orthologs. FASEB J., 
2012, 26(12), 4951-4965. 
[83] Hudson, B.D.; Tikhonova, I.G.; Pandey, S.K.; Ulven, T.; Milligan, 
G. Extracellular ionic locks determine variation in constitutive ac-
tivity and ligand potency between species orthologs of the free fatty 
acid receptors FFA2 and FFA3. J. Biol. Chem., 2012, 287(49), 
41195-411209. 
[84] Stoddart, L.A.; Smith, N.J.; Jenkins, L.; Brown, A.J.; Milligan, G. 
Conserved polar residues in transmembrane domains V.; VI.; and 
VII of free fatty acid receptor 2 and free fatty acid receptor 3 are 
required for the binding and function of short chain fatty acids. J. 
Biol. Chem., 2008, 283(47), 32913-32924.  
[85] Hoveyda, H.; Brantis, C.E.; Dutheuil, G.; Zoute, L.; Schils, D.; 
Bernard, J. Compounds, pharmaceutical composition and methods 
for use in treating metabolic disorders. International patent Appli-
cation, WO 2010/066682, June 17, 2010. 
Allosteric Ligands and Free Fatty Acid Receptors Current Topics in Medicinal Chemistry, 2013, Vol. 13, No. 1    25 
[86] Brantis, C.E.; Ooms, F.; Bernard, J. Novel amino acid derivatives 
and their use as GPR43 receptor modulators. International patent 
application, WO/2011/092284, August 4, 2011. 
[87] Lee, T.; Schwandner, R.; Swaminath, G.; Weiszmann, J.; Cardozo, 
M.; Greenberg, J.; Jaeckel, P.; Ge, H.; Wang, Y.; Jiao, X.; Liu, J.; 
Kayser, F.; Tian, H.; Li, Y. Identification and functional characteri-
zation of allosteric agonists for the G protein-coupled receptor 
FFA2. Mol. Pharmacol., 2008, 74(6), 1599-1609.  
[88] Wang, Y.; Jiao, X.; Kayser, F.; Liu, J.; Wang, Z.; Wanska, M.; 
Greenberg, J.; Weiszmann, J.; Ge, H.; Tian, H.; Wong, S.; 
Schwandner, R.; Lee, T.; Li, Y. The first synthetic agonists of 
FFA2: Discovery and SAR of phenylacetamides as allosteric 
modulators. Bioorg. Med. Chem. Lett., 2010, 20(2), 493-498.  
[89] Smith, N.J.; Ward, R.J.; Stoddart, L.A.; Hudson, B.D.; Kostenis, 
E.; Ulven, T.; Morris, J.C.; Tränkle, C.; Tikhonova, I.G.; Adams, 
D.R.; Milligan G. Extracellular loop 2 of the free fatty acid receptor 
2 mediates allosterism of a phenylacetamide ago-allosteric modula-
tor. Mol. Pharmacol., 2011, 80(1), 163-173.  
[90] Milligan, G.; Stoddart, L.A.; Smith, N.J. Agonism and allosterism: 
the pharmacology of the free fatty acid receptors FFA2 and FFA3. 
Br. J. Pharmacol., 2009, 158(1), 146-153. 
[91] Swaminath, G.; Jaeckel, P.; Guo, Q.; Cardozo, M.; Weiszmann, J.; 
Lindberg, R.; Wang, Y.; Schwandner, R.; Li, Y. Mutational analy-
sis of G-protein coupled receptor-FFA2. Biochem. Biophys. Res. 
Commun., 2011, 405(1), 122-127.  
[92] Leonard, J.N.; Chu,Z.L.; Bruce, M.A.; Boatman, P.D. GPR41 and 
modulators thereof for the treatment of insulin-related disorders. 
International patent application, WO/2006/052566, May 18, 2006. 
[93] Sina, C.; Gavrilova, O.; Förster, M.; Till, A.; Derer, S.; Hildebrand, 
F.; Raabe, B.; Chalaris, A.; Scheller, J.; Rehmann, A.; Franke, A.; 
Ott, S.; Häsler, R.; Nikolaus, S.; Fölsch, U.R.; Rose-John, S.; Jiang, 
H.P.; Li, J.; Schreiber, S.; Rosenstiel, P. G protein-coupled receptor 
43 is essential for neutrophil recruitment during intestinal inflam-
mation. J. Immunol., 2009, 183(11), 7514-7522.  
[94] Maslowski, K.M.; Vieira, A.T.; Ng, A.; Kranich, J.; Sierro, F.; Yu, 
D.; Schilter, H.C.; Rolph, M.S.; Mackay, F.; Artis, D.; Xavier, R.J.; 
Teixeira, M.M.; Mackay, C.R. Regulation of inflammatory re-
sponses by gut microbiota and chemoattractant receptor GPR43. 
Nature, 2009, 461(7268), 1282-1286. 
[95] Ge, H.; Li, X.; Weiszmann, J.; Wang, P.; Baribault, H.; Chen, J.-L.; 
Tian, H.; Li, Y. Activation of G protein-coupled receptor 43 in adi-
pocytes leads to inhibition of lipolysis and suppression of plasma 
free fatty acids. Endocrinology, 2008, 149(9), 4519-4526. 
[96] Tolhurst, G.; Heffron, H.; Lam, YS.; Parker, HE.; Habib, AM.; 
Diakogiannaki, E.; Cameron, J.; Grosse, J.; Reimann, F.; Gribble, 
F.M. Short-chain fatty acids stimulate glucagon-like peptide-1 se-
cretion via the G-protein-coupled receptor FFAR2. Diabetes, 2012, 
61(2), 364-371.  
[97] Vinolo, M.A.; Ferguson, G.J.; Kulkarni, S.; Damoulakis, G.; An-
derson, K.; Bohlooly,-Y.M.; Stephens, L.; Hawkins, P.T.; Curi, R. 
SCFAs induce mouse neutrophil chemotaxis through the GPR43 
receptor. PLoS One, 2011, 6(6), e21205. 
[98] Ichimura, A.; Hirasawa, A.; Poulain-Godefroy, O.; Bonnefond, A.; 
Hara, T.; Yengo, L.; Kimura, I.; Leloire, A.; Liu, N.; Iida, K.; Cho-
quet, H.; Besnard, P.; Lecoeur, C.; Vivequin, S.; Ayukawa, K.; 
Takeuchi, M.; Ozawa, K.; Tauber, M.; Maffeis, C.; Morandi, A.; 
Buzzetti, R.; Elliott, P.; Pouta, A.; Jarvelin, M.R.; Körner, A.; Ki-
ess, W.; Pigeyre, M.; Caiazzo, R.; Van Hul, W.; Van Gaal, L.; 
Horber, F.; Balkau, B.; Lévy-Marchal, C.; Rouskas, K.; Kouvatsi, 
A.; Hebebrand, J.; Hinney, A.; Scherag, A.; Pattou, F.; Meyre, D.; 
Koshimizu, T.A.; Wolowczuk, I.; Tsujimoto, G.; Froguel, P. Dys-
function of lipid sensor GPR120 leads to obesity in both mouse and 
human. Nature, 2012, 483(7389), 350-354. 
[99] Taneera, J.; Lang, S.; Sharma, A.; Fadista, J.; Zhou, Y.; Ahlqvist, 
E.; Jonsson, A.; Lyssenko, V.; Vikman, P.; Hansson, O.; Parikh, 
H.; Korsgren, O.; Soni, A.; Krus, U.; Zhang, E.; Jing, X.J.; Es-
guerra, J.L.; Wollheim, C.B.; Salehi, A.; Rosengren, A.; Renström, 
E.; Groop, L. A systems genetics approach identifies genes and 
pathways for type 2 diabetes in human islets. Cell Metab., 2012, 
16(1), 122-134.  
[100] Suzuki, T.; Igari, S.; Hirasawa, A.; Hata, M.; Ishiguro, M.; Fujieda, 
H.; Itoh, Y.; Hirano, T.; Nakagawa, H.; Ogura, M.; Makishima, M.; 
Tsujimoto, G.; Miyata, N. Identification of G protein-coupled re-
ceptor 120-selective agonists derived from PPARgamma agonists. 
J. Med. Chem., 2008, 51(23), 7640-7644. 
[101] Shimpukade, B.; Hudson, B.D.; Hovgaard, C.K.; Milligan, G.; 
Ulven, T. Discovery of a potent and selective GPR120 agonist. J. 
Med. Chem., 2012, 55(9), 4511-4515. 
[102] Sun, Q.; Hirasawa, A.; Hara, T.; Kimura, I.; Adachi, T.; Awaji, T.; 
Ishiguro, M.; Suzuki, T.; Miyata, N.; Tsujimoto, G. Structure-
activity relationships of GPR120 agonists based on a docking simu-
lation. Mol. Pharmacol., 2010, 78(5), 804-810.  
[103] Watson, S.J.; Brown, A.J.; Holliday, N.D. Differential signaling by 
splice variants of the human free fatty acid receptor GPR120. Mol. 
Pharmacol., 2012, 81(5), 631-642.  
[104] Arkawa, K.; Nishimura, T.; Sugimoto, Y.; Takahashi, H. Novel 
isoindolin-1-one derivative. International patent application, WO 
2010/104195, September 16, 2010. 
[105] Ma, J.; Novack, A.; Nashashibi, I.; Pham, P.; Rabbat, C.J.; Song, J.; 
Shi, D.F.; Zhao, Z.; Choi, Y.-J.; Chen, X. Aryl GPR120 receptor 
agonists and uses therof. International patent application, WO 
2010/048207, April 29, 2010. 
[106] Hashimoto, N.; Sasaki, Y.; Nakama, C.; Ishikawa, M. Novel 
phenyl-isoxayol-3-ol derative. United States patent application, US 
2010/0130559, May 27, 2010. 
[107] Hara, T.; Hirasawa, A.; Sun, Q.; Sadakane, K.; Itsubo, C.; Iga, T.; 
Adachi, T.; Koshimizu, T.; Hashimoto, T.; Asakawa, Y.; Tsuji-
moto, G. Novel selective ligands for free fatty acid receptors 
GPR120 and GPR40. Naunyn Schmiedebergs Arch. Pharmacol., 
2009, 380(3), 247-255. 
[108] Burns, R.N.; Moniri, N.H. Agonsim with the omega-3 faty acids ?-
linolenic acid and docosahexaenoic acid mediates phosphorylation 
of both the short and long isoforms of the human GPR120 receptor. 
Biochem. Biophys. Res. Commun., 2010, 396(4), 1030-1035. 
[109] Yousefi, S.; Cooper, P.R.; Potter, S.L.; Mueck, B.; Jarai, G. Clon-
ing and expression analysis of a novel G-protein-coupled receptor 
selectively expressed on granulocytes. J. Leukoc. Biol., 2001, 
69(6), 1045-1052. 
[110] Bouchard C.; Pagé, J.; Bédard, A.; Tremblay, P.; Vallières, L. G 
protein-coupled receptor 84, a microglia-associated protein ex-
pressed in neuroinflammatory conditions. Glia, 2007, 55, 790-800. 
[111] Nagasaki, H.; Kondo, T.; Fuchigami, M.; Hashimoto, H.; Sugi-
mura, Y.; Ozaki, N.; Arima, H.; Ota, A.; Oiso, Y.; Hamada, Y. In-
flammatory changes in adipose tissue enhance expression of 
GPR84; a medium-chain fatty acid receptor: TNF? enhances 
GPR84 expression in adipocytes. FEBS Lett., 2012, 586(4), 368-
372. 
[112] Takeda, S.; Yamamoto, A.; Okada, T.; Matsumura, E.; Nose, E.; 
Kogure, K.; Kojima, S.; Haga, T. Identification of surrogate ligands 
for orphan G protein-coupled receptors. Life Sci., 2003, 74(2-3), 
367-377. 
 
 
Received: November 16, 2012 Revised: November 29, 2012 Accepted: November 30, 2012 
 
 
 
PMID: 23409763 
